Hepion raises authorized common stock to 750,000,000 shares via Delaware Certificate of Amendment

Hepion Pharmaceuticals, Inc.

Certificate of Amendment filed with the Delaware Secretary of State and effective October 1, 2026, increased Hepion's authorized common stock to 750,000,000 shares.
The filing does not state the prior authorized share count, the reason for the increase, or any planned issuance, financing or pricing terms tied to the new shares.
Full text of the Certificate of Amendment is attached as Exhibit 3.1; the 8-K is signed by Interim CEO Gary Stetz and dated October 2, 2026.
Hepion's common stock (HEPA) is quoted on the OTC QB; no change to par value of $0.0001 per share was disclosed.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.